Developing a Robust Assay
A successful experiment begins with an assay designed to answer the right question—not simply to produce the largest signal.
Assay development is often described as optimization: adjust reagent concentrations,
improve signal-to-background, reduce variability, and establish reproducibility.
Those things matter. But a robust assay must also preserve the biology needed to
answer the scientific question.
For screening in particular, assay development requires balancing biological
relevance, sensitivity, reproducibility, throughput, reagent consumption, cost,
automation, and the mechanisms of activity you hope to detect. Those requirements
do not always point toward the same experimental conditions.
Start with the Scientific Question
Before choosing a plate, detection technology, or screening format, define what
the experiment needs to tell you.
What biological event are you measuring? What would constitute activity? What
decision will you make from the result?
The choice of assay conditions can influence the biology that is observed. In an
enzyme assay, for example, substrate concentration, reaction time, pre-incubation,
protein construct, and other conditions can affect sensitivity to different
mechanisms of inhibition.
An assay is therefore not a neutral observer: how the experiment is
designed can influence what you are capable of discovering.
Know Your Reagents
An assay cannot be more reliable than the reagents on which it depends.
Proteins, enzymes, substrates, antibodies, cell lines, reporter systems, and
reference compounds should be sufficiently characterized for their intended use.
Important considerations can include purity, concentration, activity, stability,
homogeneity, and lot-to-lot consistency.
For purified proteins in particular, knowing that material is present is not
necessarily the same as knowing that it is biologically active or in the
appropriate state.
Reagent availability also matters. An assay that consumes large amounts of scarce
protein may work beautifully at small scale but be impractical for a campaign
involving hundreds of microplates.
Choose the Readout for the Experiment
Many biological events can be measured in more than one way.
Fluorescence, luminescence, absorbance, fluorescence polarization, TR-FRET,
AlphaScreen/AlphaLISA, imaging, and other technologies each have strengths and
limitations. The choice should reflect the biology, available reagents, required
sensitivity and throughput, instrumentation, cost, and plans for subsequent
validation.
Every detection technology also introduces potential sources of interference.
Fluorescent compounds can affect optical assays; compounds may interfere with
detection chemistry; and in coupled assays a compound can inhibit an enzyme in
the detection system rather than the biological target itself.
Understanding how the signal is generated is therefore part of understanding
the assay.
Optimize Systematically—and Iteratively
Assay optimization is rarely a linear process.
Variables such as pH, ionic strength, reagent concentrations, detergent, assay
volume, temperature, incubation time, order of addition, plate type, and detection
conditions can interact. Changing one parameter may alter the optimum for another.
A practical strategy is to test groups of variables, establish conditions that
improve performance, and then evaluate additional parameters under those
conditions. Earlier choices may need to be revisited as the assay evolves.
The goal is not to find a theoretical optimum for each variable independently.
It is to develop a complete experimental system that performs reproducibly while
retaining the biology you need to measure.
Measure Variability, Not Just Signal
A large assay window is useful only if it is reproducible.
Positive and negative controls define the experimental range and provide reference
points for normalization. They should be incorporated throughout assay development
and, ultimately, into every screening plate.
Signal-to-background, coefficient of variation (CV), and Z′ are useful measures
of assay performance. As a general screening benchmark, CVs below approximately
10% and Z′ values above 0.5 are desirable, although appropriate standards depend
on the assay and biological system.
These statistics should guide assay development rather than become the scientific
objective.
A condition that maximizes Z′, for example, may reduce sensitivity to the activity
you are trying to discover. Statistical robustness and biological sensitivity
sometimes require compromise.
Establish a Reliable Concentration-Response Relationship
A robust assay should do more than distinguish an active sample from an inactive
one. It should be able to measure how activity changes with
concentration.
Titration experiments are an important part of assay development. Titrating key
reagents and reference compounds helps define the assay window, identify
appropriate working concentrations, and determine whether the assay produces the
expected concentration-dependent response. These experiments can also reveal
problems that may be hidden by measurements made at a single concentration.
For active compounds, a well-designed concentration-response experiment allows
potency to be estimated quantitatively, typically through values such as
IC50 or EC50. The shape and reproducibility of the
concentration-response curve can be as informative as the calculated potency
itself. Poorly defined plateaus, unusually steep or shallow slopes, or inconsistent
curves may indicate assay limitations, compound interference, solubility problems,
or more complex biology.
Accurate concentration-response measurements become especially important after
screening, when medicinal chemistry begins to explore
structure–activity relationships (SAR). Chemists need to know
whether a structural modification has made an analog more potent, less potent,
or essentially unchanged. If assay variability is comparable to the apparent
difference between two compounds, that distinction cannot be made with confidence.
An assay intended to support medicinal chemistry therefore needs sufficient
precision and reproducibility to distinguish meaningful differences in potency
across a compound series. As chemistry progresses, repeated concentration-response
measurements provide quantitative evidence for establishing SAR and deciding
which structural changes—and which compounds—to pursue.
A screening assay finds activity; a quantitative assay helps optimize it.
Design with Screening in Mind
An assay that works at the bench is not necessarily ready for high-throughput
screening.
Miniaturization changes volumes, surface-to-volume relationships, evaporation,
mixing, dispensing accuracy, reagent consumption, and sometimes assay kinetics.
Automation also imposes practical constraints on the number of additions,
incubation times, plate handling, and order of operations.
Whenever possible, assay development should eventually reproduce the conditions
of the intended screen: the same plate format, liquid-handling methods, controls,
incubation periods, detection technology, and analysis workflow.
A pilot study can then reveal plate effects, variability, automation problems,
compound-related artifacts, or other issues that may not be apparent during
small-scale development.
Plan How You Will Recognize a False Positive
A primary screening result is an observation, not proof of mechanism.
Compounds may interfere with detection, aggregate proteins, affect reporter
systems, inhibit coupled enzymes, produce cytotoxicity, or generate activity
through mechanisms unrelated to the intended target.
The strategy for distinguishing these effects should be considered
before the primary screen begins.
Depending on the assay, follow-up may include repeat testing,
concentration-response experiments, orthogonal detection methods, target-minus
assays, interference controls, cytotoxicity measurements, selectivity assays,
or assays in a different biological context.
Think Beyond the Hit
A screening hit is the beginning of an investigation.
Primary screening identifies compounds associated with an experimental signal.
Subsequent experiments determine whether that signal is reproducible,
concentration-dependent, biologically meaningful, target-related, and sufficiently
compelling to pursue.
Thinking about those experiments during assay development can influence the
choice of primary assay itself. An orthogonal assay based on a different
measurement principle, for example, can be considerably more informative if it
has been anticipated before hundreds of hits need to be evaluated.
The objective is not to design an assay that produces hits.
It is to design an experimental strategy capable of producing reliable
evidence.
When Should You Talk to the DDRC?
Ideally, before everything has been optimized.
Investigators do not need to arrive with a screening-ready assay. Early discussion
can help evaluate the biological question, reagents, assay format, controls,
detection technology, miniaturization strategy, automation requirements, and
plans for validation.
Sometimes the appropriate next step is high-throughput screening. Sometimes it
is a pilot experiment, additional reagent characterization, an alternative assay,
or a different approach entirely.
The assay should serve the scientific question—not the other way around.